



FEATURE

Innovating R&D with the cloud

Business transformation could require cloud-enabled data, ecosystems, and services

Todd Konersmann, Nicholas Merizzi, Sudi Bhattacharya, Diana Kearns-Manolatos, and Jay Parekh

Life sciences and health care organizations appear at an inflection point with a unique opportunity to advance public/private information-sharing for a break-the-glass scenario that could save lives.

Cloud-enabled business transformation for R&D

THE PANDEMIC IS often credited with helping to accelerate change, challenge the status quo, and drive innovative research and development (R&D) solutions. Organizations the world over are innovating quickly, whether it is making ventilators (largely) from car parts,¹ creating contact-tracing apps,² or investing in R&D for public health.³ But the technology infrastructure required to support innovation and data strategies can be substantial. After all, upfront technology investment into on-premise infrastructure is heavy, procurement periods are long, and fixed costs are considerable—and together, these may become a barrier to progress. While many global organizations are embracing cloud infrastructure to support remote work,⁴ many may be missing out on optimizing their cloud and data strategies to enable innovation and R&D.

The cloud could be uniquely positioned to support R&D given that it can provision infrastructure almost instantaneously, scale up or down as the need shifts, and provide physical data center and virtual network security. What's more, organizations can innovate secure digital applications and platforms more rapidly. Finally, the cloud brings a capacity to store and integrate information across robust networks. So, organizations can have interoperable data, and can engage in teamwork, collaboration, and cocreation.

METHODOLOGY

To understand the potential of cloud technology for **next-generation R&D**, in September and October of 2020, we interviewed 10 specialists in business transformation, cloud, data engineering, and R&D

whose input informed the insights of this article.

Based on our research, we found three distinct approaches related to cloud-enabled data, ecosystems, and services (figure 1).

While organizations across all industries can benefit, the opportunity may be especially relevant in the life sciences and health care (LSHC) industry. The global pandemic has highlighted the need for global coordination with omnichannel audiences across public, private, academia, and consortiums. This paper examines the different ways in which the cloud can enable R&D across the LSHC industry and beyond.

LSHC: WHAT COVID-19 TEACHES US ABOUT CLOUD-ENABLED COLLABORATIVE RESEARCH


Is the pandemic a “break the glass” scenario for cloud-enabled R&D in LSHC?

The technology to bring together real-world and clinical data, securely, at scale, and at velocity—the cloud—has been there all along. By urgent necessity, the pandemic has hypercharged this transformation for global collaboration around shared research objectives.

- **Pharmaceutical research** is seeing unprecedented levels of collaboration. For COVID-19, 213 vaccines are in development and 319 potential treatments in progress.⁵
- **Biopharma companies** have reconfigured their individual clinical operations and trials to manage efficiency and cost, and better connect with patients.⁶

FIGURE 1

Three key cloud approaches for next-generation R&D



Source: Deloitte analysis.

- **Health care organizations** are maturing in using advanced analytics and machine learning (ML) for diagnostics and are sharing real-world evidence from clinical notes, lab reports, pathology images, and radiology scans. Deloitte research shows that 84% of physicians expect secure, efficient sharing of patient data integrated into care in the next 5–10 years.⁷
- **Bioinformatics** have progressed to sequence and analyze the RNA of SARS-CoV-2 (the virus that causes COVID-19) to develop antiviral drugs by drawing on ML tools.⁸

Deloitte’s research on radical data interoperability reveals that 60% of US LSHC organizations host more than half of their applications on the cloud already.⁹ However, nonstandardized data infrastructures pose a challenge in coordination¹⁰ and data interoperability within and across

organizations. This is where cloud technologies can help advance transformation now and into the future.

The cloud is an enabler of data, and cloud and data modernization strategies are inextricably intertwined.¹¹ As human genome sequencing data volumes grow to an expected 40 exabytes by 2025,¹² and as scientists spend up to 30%–40% of their time searching for, aggregating, and cleansing data,¹³ the cloud may well be a force multiplier to get drugs to market faster and cheaper. In fact, it’s already set the world record¹⁴ for elastic analysis of genomic data.¹⁵ And Deloitte research shows that shared infrastructure and resources for master protocols can reduce the research cycle time by 13%–18% and overall cost savings of 12%–15%.¹⁶ The question becomes: How does cloud enable such efficiencies and cost savings?

Innovating innovation technology for LS&HC R&D across three core approaches

CLOUD DATA PLATFORMS

Organizations are beginning to understand a centralized data warehouse isn't the only model. There are numerous cloud data platform options, including enterprise data management, data exchanges, open architecture strategies, the centralized data warehouse, and data lakes each with their unique advantages.

Enterprise data management

It's common for valuable laboratory data to be saved on local hard drives, thumb drives, and storage area networks, thus introducing storage capacity, searchability, and security challenges. The cloud gives organizations various solutions to ingest, transform, analyze and share millions of existing records with flexibility and at scale to make data a reusable asset across teams. Cloud-enabled enterprise data management platforms with a shared data lake are one common solution, and our interviews revealed LSHC organizations, in particular are beginning to explore a new, emerging operating model to manage data across the organization in the form of "data-sharing neighborhoods" to generate cross-domain insights and to share data with regulators.

The biotechnology company **Biogen**, for example, produced 50 images for a single sample per day, which were saved in local, electronic lab notes that were archived every six months. This created a data access and searchability challenge, which they addressed via the cloud.¹⁷ In another instance, **Pfizer** launched its **Scientific Data Cloud** to make research data shareable, customizable, and reusable for researchers, data scientists, software engineers, and operations. The platform was designed to enable automated scalable analysis for precision medicine to find individualized treatments for diseases like cancer, and it provides a foundation for a longer-term data marketplace.¹⁸

External data exchanges

Cloud providers have started to offer data exchanges with clinical data, real-world evidence, and imaging data to power R&D studies and match drugs to patient populations.¹⁹ Over the next five years, cloud-enabled data exchanges and marketplaces could disintermediate data aggregators and resellers and provide new opportunities for large-scale and secure data transfers across organizations. These data marketplaces are expected to become increasingly important and could lead to a world where digital health data enables "learning health care," with real-time clinical interventions that save lives.

The **National Institutes of Health's (NIH) All of Us Research Program** will collect genomic data for 1 million people over 20 years for collaborative research.²⁰ **The UK National Health System's Biobank** generated 1.5PB+ of genetic, clinical, behavioral, and biometric data in its global population study.²¹ These projects are a concerted effort to create massive data repositories that can be used to support future internal or external data exchanges.

Merck, a leading global biopharmaceutical company, deployed an enterprisewide cloud-based real-world data (e.g., medical claims, EMR, etc.) analytics platform called the "Real World Data Exchange" to advance product development and commercialization. Merck's Real World Data Exchange is an open, API-first platform and serves a broad set of stakeholders decreasing the time to insight-generation and fostering collaboration to positively impact all aspects of the product life cycle.²²

Creating more open and interoperable systems

It may be a challenge for commercial **pharmaceutical** companies to share proprietary data today, but many are sharing noncompetitive, HIPAA-compliant placebo data across studies without privacy concerns. They are doing so via an application programming interface (API)-first approach (a strategy which anticipates data-sharing across applications by design and allows for

standardized, programmatic connection of applications). This approach creates a technical foundation for interoperable data-sharing as future collaboration incentives and cultural norms change and as an alternative to more open models (i.e. open APIs). The API-first organizations have frameworks that:

1. Rank, flag, and categorize data sets for regulatory purposes
2. Manage shareable and nonshareable data
3. Establish baseline and incremental controls as greater security is needed

In health care, **wearables** are API-first technologies that allow data to be shared from devices to digital apps with privacy controls in place. Available in shareable and manageable formats, this data can be distributed across organizations for R&D purposes.

Cloud data warehouses, storage archives, and more

The cloud encrypts all data at rest and offers a variety of storage options for data with high input/output requirements. It also allows unique scale-up/scale-down capabilities. These advantages enable researchers to ingest petabytes of data at a given time and run queries by scaling up compute on-demand and temporarily, only paying for additional capacity when used. At the same time, the cloud offers dense/cold archive storage for long-term archival needs.

SCALABLE CLOUD ECOSYSTEM INFRASTRUCTURE

A vast majority (94%) of respondents believe real-world evidence in R&D will become increasingly important by 2022.²³ A scalable cloud ecosystem would allow hospitals to share real-world data across their internal and external public/private networks to accelerate the entire ecosystem's ability to target novel diseases or subpopulations who express major diseases differently. This is the

cloud's *network effect* in action—with just one important data set. To play that scenario forward, collaborative cloud ecosystems require the right operating model, such as a third-party arbiter, and incentives to ensure data safety, risk management, and IP protection—which is a journey still in progress to achieving these network benefits.

Research has shown that a *network of ecosystems* can help harness and accelerate distributed innovation for complex, externally-driven problems.²⁴ It can facilitate a more collaborative approach and enables more diverse perspectives.²⁵ Deloitte's *Transforming Clinical Development* research has found some organizations are already experimenting with transformative approaches to drug development, such as use of real-world evidence and adaptive trials. Scaling the use of these approaches requires an ecosystem model wherein companies work collaboratively and transparently with multiple stakeholders. From a *technology* perspective, companies require interoperable data, knowledge management, and analytics platforms and processes, as well as scalable and secure *cloud* capabilities.²⁶

From an *R&D* perspective, Deloitte's 2020 Real World Evidence survey reveals that 16 out of 17 participating companies are using cloud platforms for real-world evidence and all the surveyed mature companies have a centralized, primarily cloud-based analytics platform.²⁷ A scalable cloud ecosystem would allow hospitals to share real-world data across their internal and external public/private networks to accelerate their ability to target rare and novel diseases and cater to underrepresented populations. This could also open the door to cloud ML services to predict acute events like sepsis and understand disease states and linkages, such as congestive heart failure and diabetes.

The COVID-19 Healthcare Coalition, a private sector-led collaborative response to coronavirus, developed a cloud-native platform with secure/authenticated cloud storage, a data ingestion

pipeline to sort/understand 300+ curated resources, and a big query searchable metadata repository for secure, scalable collaborative research. The platform has enabled members to support frontline responders and researchers and to improve treatment, regiments, vaccines, and device testing.²⁸

However, there are challenges too. Take **biomedical R&D**, for example, where researchers lack coding expertise, and therefore the technology transformation ability. For this very reason, as the volume of genomics data has grown, most biomedical researcher organizations have embraced PaaS/SaaS data platforms powered by the cloud. *But these point solutions have created data silos* that can make it challenging to create clean and shareable data as part of a broader digital ecosystem. As organizations realize that data is an asset beyond a single analysis, this creates an opportunity for an API-enabled, cloud-native digital ecosystem.

ADVANCED CLOUD SERVICES FOR LSHC R&D

Two of the top outcomes that life sciences companies are attempting to achieve with AI are enhancing existing products and creating new products and services. Cloud AI, ML, and the internet of things (IoT) services can provide greater innovation speed and agility across the R&D value chain. In fact, some organizations are exploring AI to better manage clinical trial data.²⁹ Some are also using cloud AI services to coordinate and accelerate recruiting and matching patients with clinical trials sites,³⁰ to analyze existing drugs on the market, to screen drugs for other diseases (such as COVID-19),³¹ and potentially to detect future disease outbreaks before they occur.³²

By aiding physicians with real-time data-driven diagnosis and treatment plans, AI-based solutions can play an important role in streamlining clinical diagnostics.³³ In cancer diagnostics, for example, both false positives and false negatives pose real challenges, but part of the problem with training AI/ML models for diagnostics is getting a large enough data sample set to detect lung and pancreatic cancer for example—typically found in stage 3—at stage 1. Public and private organizations are using cloud ML to improve accuracy of cancer diagnoses in private sector research³⁴ and for early diagnosis.³⁵

- **Takeda, a pharmaceutical company**, used a cloud-enabled data platform and advanced deep learning to predict at 92% accuracy (a 40-percentage point improvement) the patients likely to respond and improve during a nonalcoholic steatohepatitis and treatment-resistant depression therapeutics trial.³⁶
- **Johnson & Johnson, a pharmaceutical and consumer packaged goods company**, connected siloed data with intelligent automation, invested in cloud/core modernization, and aligned its cyber strategy to improve predictive decision-making, expedite clinical trial screening, and improve financial processing across 300,000 transactions for a hypertension drug trial.³⁷
- **Mayo Clinic, the hospital network**, announced it would use cloud AI/ML services to store, compute, and analyze patient data to advance the diagnosis and treatment of disease³⁸ and bring the Mayo Clinic Platform—a digital extension of the organization’s capabilities—worldwide.³⁹

THE NIH ON ADVANCING PUBLIC/PRIVATE PARTNERSHIPS

Bringing all three of these approaches together, **the NIH** has made progress with **the NIH Data Commons** to store, share, access, and interact with digital files generated from biomedical research.⁴⁰ Its **Accelerating COVID-19 Therapeutic Interventions and Vaccines partnership** has brought together over a dozen biopharma companies to standardize collaborative frameworks across vaccine and therapeutic R&D from preclinical evaluation to immune-response testing.⁴¹ Through the **NIH Science and Technology Research Infrastructure for Discovery, Experimentation, and Sustainability Initiative**, the organization explores cloud and ML capabilities⁴² to generate, analyze, and share research data with commercial and 2,500 NIH-funded institutions.⁴³ Most recently, the **NIH National Center for Advancing Translational Sciences' (NCATS's) National COVID Cohort Collaborative Data Enclave (N3C)** has created a centralized, secure, and cloud-enabled data platform to analyze real-world COVID-19 patient data for factors and long-term health consequences across 57 sites.⁴⁴ For its part, the **Rapid Acceleration of Diagnostics initiative** aims to expedite innovation around rapid COVID-19 testing,⁴⁵ undetected cases,⁴⁶ and public health monitoring.⁴⁷

HOW BROADCOM INNOVATED A CLOUD-NATIVE DIGITAL APPLICATION TO MANAGE WORKFORCE SAFETY WHILE PROTECTING DATA PRIVACY

Situation

As organizations responded to the pandemic, many have adapted to remote work. However, for Broadcom, a global infrastructure technology company that employs essential workers, engineers, and fabrication units, remote solutions were not an option. Faced with new workforce safety and risks challenges related to COVID-19 and the need to operate in a physical working environment, Broadcom wanted to go beyond standard social distancing, personal protective equipment (PPE), and hygiene, and sought to rapidly innovate a digital solution to alert and act on potential exposure—with employee privacy and local regulations in mind.

Approach

The cloud-native approach allowed the organization to quickly innovate a digital solution for data-sharing and analysis with worker privacy and data security considerations managed by the organization's global privacy officer. The cloud application allowed Broadcom to:

- Collect relevant personal worker information on the digital app on employee mobile devices
- Integrate the data into internal systems, organization policies, security protocols, and global communications
- Mine, aggregate, and analyze the data to identify potential COVID-19 exposure
- Alert potentially at-risk individuals and initiate location-based cleaning protocols

Result

A digital, cloud-data-sharing application was launched at scale in under 10 weeks across 10 countries for 15,000+ workers and 5,000 contractors that managed 350,000+ survey collections and work passes following daily symptom analysis and 250,000 automated workplace check-ins.

Source: Deloitte analysis.

Five recommendations to advance the cloud-enabled data strategy across industries

Many organizations across industries are looking to modernize data platforms to reduce data costs, harness big data, create more data analysis flexibility, and tap into powerful artificial intelligence tools. Cloud technology could be the key enabler for them.⁴⁸ Success may boil down to scalable and secure cloud data platforms to support interoperable data strategies, an ecosystem for collaborative analysis, and services to expedite and scale R&D innovation with low latency.

To give just one example of how these aspects are coming together in another industry, the **US DoD— Defense Information Systems Agency Joint AI Center** is looking to advance its intelligence strategy with a common, shared cloud-native/edge platform across 6–7 mission areas. It is expected to bring in multiple petabytes of data that would be impossible to move otherwise. The solution, referred to as the **Joint Common Foundation (JCF)** is designed to include high-level controls based on security clearance for various DoD organizations to access, buy, and acquire AI solutions and the data behind them. There is expected to also be defensive cyber operations including incident response, vulnerability management, continuous monitoring, and zero-trust architecture. Ultimately, the AI infrastructure could enable war fighters with secure data/tools for speed to decision that enable and enhance national security.

Going forward, there are five key takeaways to keep in mind (figure 2).

1. Make data-sharing FAIR in the cloud.

Cloud-native databases provide elasticity and reduced total cost of ownership.⁴⁹ Guide cloud data migration by making sure it is findable,

accessible, indexable, and reusable (F.A.I.R.) for collaborative research. Any R&D organization needs a repository of searchable and discoverable information. This baseline gives a perspective to a new data scientist or engineer to consider in order to focus research, build on existing data, implement improved practices, and find the white space for innovation.

2. Build a business case for data-sharing.


Integration patterns across organizations should change to enable data-sharing. That would require building and articulating a well-defined business case across a shared purpose that addresses data use, confidentiality requirements, and controls. Consider articulating why both/all parties should want to share the data, how IP/ownership would be protected, what incentives there are, and adhere to industry standards/protocols for data integrity. In many industries, there may be commercial and other incentives that directly conflict with data-sharing, in which case, finding a shared purpose and realigning incentive models based on that purpose can provide a useful starting point.

3. Address data privacy.

Cloud platforms should be designed with the proper governance, compliance, and security boundaries in place. They should be configured to industry norms, but be porous enough to encourage data-sharing, trust building, and network integrity maintenance. This type of open data platform would be nearly impossible on premise. Cloud, however, is built to support federated data models, with identity and access management, encryption and network security frameworks, and controls at each layer.⁵⁰ It also has the inherent ability to create connected “islands” that can be crossed for private and secure collaboration. For data privacy, consider obfuscating, anonymizing, deidentifying, or pseudonymizing the data

FIGURE 2

Five recommendations for cloud-enabled R&D business transformation



Source: Deloitte analysis.

based on the level of control needed for trusted actors across the ecosystem.

- 4. Build the right cloud engagement model.** Organizations can consider **service-oriented**, **data-oriented**, and **process-oriented** architectures.⁵¹

Service-oriented approaches might include **SaaS solutions** that allow for shared **services**, like online task management, work planning, and collaboration tools, across cloud-native web-based applications. These solutions can enable exploratory R&D and teaming on a broader scale for greater transparency. They have the ability to manage financial incentives based on contribution, protect the IP, and are basically a “try as you go” model. Additionally, **IaaS models** allow for ideation with ease and accessibility given the ability to rent standardized cloud environments for hours at a time (and at a fraction of the cost/time on the secondary market) and to tap into hundreds of cloud

services. R&D can benefit from the ability to build a hypothesis, incubate an idea, and if it fails, scale down—if it succeeds, burst capacity across teams, organizations, and geographies with identical test environments across increasingly *open and portable* or *interoperable and proprietary* tech stacks.

In terms of **data approaches**, PaaS enables the developer with rapid delivery and prototyping capability to test ideas. When combined with **Data-as-a-Service**, PaaS allows organizations to replicate and propagate data across the R&D environment for a single version of truth. This model generally needs some level of agreement on API standards to facilitate reusable data calls and queries for an open and interoperable network.⁵²

Finally, with **process-oriented** R&D, organizations can integrate innovation into the work **processes**. For example, **Google’s** R&D

follows a hybrid research model that can make the line between research and engineering blurry by writing R&D as near-production code to accelerate production timelines.⁵³

5. Embrace cloud services for automation, analytics, and ML. R&D and innovation teams are using cloud services for everything from automated research⁵⁴ and next best action recommendations⁵⁵ to advanced military-grade AI programs. Investigate which of the many available services could advance the organizations broader digital ecosystem for innovation.

Whether on the front lines of LSHC R&D or working in another industry looking to innovate new products and services, a solid cloud-enabled data strategy may increasingly be a cornerstone to advancing the organizational journey toward becoming a data-driven digital enterprise in a data-driven digital ecosystem. Cloud technology could be uniquely positioned to serve as the digital core across a variety of enablement models to support secure collaboration and innovate the future.

The stakes are high, but the lessons could be transformative for R&D across industries.



Endnotes

1. Peter Valdes-Dapena, "Tesla's working on making ventilators from car parts," CNN, April 6, 2020.
2. Russell Brandom, "Apple and Google announce new automatic app system to track COVID exposures," The Verge, September 1, 2020.
3. Martyn Landi, "Government announces £32m in R&D funding for futuristic healthcare projects," Yahoo News, September 7, 2020.
4. David Linthicum et al., *The future of cloud-enabled work infrastructure: Making virtual business infrastructure work*, Deloitte Insights, September 23, 2020.
5. Milken Institute, "COVID-19 treatment and vaccine tracker," November 4, 2020.
6. Deloitte, "Using technology to boost clinical supply chain performance," accessed October 13, 2020.
7. Doug Billings et al., *Improved clinical efficiency and quality: How can medtech meet physicians' digital technology needs?*, Deloitte Insights, September 24, 2020.
8. ABI Research, *Cloud-based AI in a post-COVID-19 world*, accessed October 13, 2020.
9. David Biel et al., *Radical interoperability: Picking up speed to become a reality for the future of health*, Deloitte Insights, October 24, 2019.
10. Matthew Herper, "Data show panic and disorganization dominate the study of Covid-19 drugs," Stat News, July 6, 2020.
11. Tom Davenport, Ashish Verma, and David Linthicum, *Data modernization and the cloud: Which trend is driving the other?*, Deloitte Insights, August 26, 2019.
12. *Medical Futurist*, "The genomic data challenges of the future," October 27, 2018.
13. AWS Web Day 2020—Life Sciences Business Tracks, "Benchling: The next digital transformation of life sciences R&D," 2020.
14. PR Newswire, "Children's Hospital of Philadelphia and Edico Genome achieve fastest-ever analysis of 1,000 genomes," October 19, 2017.
15. Chris Munns, "Accelerating precision medicine at scale," AWS Compute Blog, November 16, 2017.
16. Neil Lesser and Bushra Naaz, *Master protocols: Shifting the drug development paradigm*, Deloitte Insights, September 17, 2018.
17. AWS Web Day 2020—Life Sciences Technical Tracks, "TetraScience: Unifying R&D data in the cloud—making data truly accessible and actionable," accessed October 13, 2020.
18. AWS Web Day 2020—Life Sciences Business Tracks, "Pfizer: Building Pfizer's scientific data cloud on AWS," accessed October 13, 2020.
19. AWS, "AWS data exchange," accessed October 13, 2020.
20. National Institutes of Health, "The future of health begins with you," accessed October 13, 2020.
21. AWS Web Day 2020—Life Sciences Business Tracks, "Paradigm4: 1 billion regressions in an hour—unlocking the promise of the UK Biobank," accessed October 13, 2020; UK Biobank, "UK Biobank creates cloud-based health data analysis platform to unleash the imaginations of the world's best scientific minds," August 18, 2020.

22. AWS Events YouTube Channel, "AWS re:Invent 2019: Merck drives innovation with a 'real-world data exchange' on AWS [ENT232-S]," 1: 02: 52, December 4, 2019.
23. Jeff Morgan et al., *RWE focus is shifting to R&D, early investments begin to pay off: How can others catch up?*, Deloitte Insights, June 11, 2020.
24. Elizabeth J. Altman and Frank Nagle, "Accelerating innovation through a network of cosystems," *MIT Sloan Management Review*, June 9, 2020.
25. Michael Main, Michael Schwartz, and Wendy Gerhardt, *Findings from the Deloitte 2019 Health Care CEO Perspectives Study: Unique insights from industry leaders*, Deloitte Insights, January 17, 2020.
26. Sonal Shah et al., "Bringing new therapies to patients: Transforming clinical development," November 2020.
27. Morgan et al., *RWE focus is shifting to R&D, early investments begin to pay off*.
28. The MITRE Corporation, "COVID-19 healthcare coalition forms to support the U.S. healthcare system and help protect U.S. populations," press release, March 23, 2020.
29. Aditya Kudumala, Dan Ressler, and Wendell Miranda, *Scaling up AI across the life science value chain: Enhancing R&D, creating efficiencies, and increasing impact*, Deloitte Insights, November 4, 2020.
30. Deep6 AI, "How it works," accessed October 13, 2020.
31. BenevolentAI, "What we do," accessed October 13, 2020.
32. BlueDot, "Anticipate outbreaks. Mitigate risk. Build resilience," accessed October 13, 2020.
33. Kumar Chebrolu, Dan Ressler, and Hemnabh Varia, *Smart use of artificial intelligence in health care: Seizing opportunities in patient care and business activities*, Deloitte Insights, October 22, 2020.
34. Erum Ahmed, "Google Cloud's AI is being used by the US government to improve the accuracy of cancer diagnoses," *Business Insider*, September 3, 2020.
35. Khari Johnson, "Google Cloud secures U.S. military AI cancer research contract," *VentureBeat*, September 2, 2020.
36. Deloitte, "Cloud-based machine learning in health care creates patient-centered treatments," accessed October 13, 2020.
37. Bill Briggs, Scott Buchholz, and Sandeep Kumar Sharma, *Macro technology forces: A second look at the pillars of past, current, and future innovation*, Deloitte Insights, January 15, 2020.
38. Heather Landi, "Mayo Clinic taps Google Cloud as strategic partner to accelerate innovation in AI, analytics and digital tools," *Fierce Healthcare*, September 10, 2019.
39. Laura Dyrda, "Mayo ramping Google partnership back up and plans to open AI factory," *Becker's Hospital Review*, September 2, 2020.
40. NIH, "New models of data stewardship—Data commons pilot," May 13, 2019.
41. NIH, "NIH to launch public-private partnership to speed COVID-19 vaccine and treatment options," news release, April 17, 2020.
42. Evan Sweeney, "Google Cloud joins NIH initiative to create a biomedical database," *Fierce Healthcare*, July 25, 2018.
43. NIH, "About the STRIDES Initiative," July 21, 2020.
44. National Center for Advancing Translational Sciences, "Announcement: Access to the COVID-19 data analytics platform now open," September 2, 2020.

45. NIH, "Rapid Acceleration of Diagnostics (RADx)," accessed October 13, 2020.
46. NIH, "NIH begins study to quantify undetected cases of coronavirus infection," news release, April 10, 2020.
47. NIH, "NIH awards contracts to develop innovative digital health technologies for COVID-19," news release, September 15, 2020.
48. Davenport, Verma, and Linthicum, *Data modernization and the cloud*.
49. Andrew J. Brust and Yiannis Antoniou, *Key criteria for evaluating cloud database platforms*, GigaOm, July 8, 2020.
50. NIH, "NIH to launch public-private partnership to speed COVID-19 vaccine and treatment options."
51. David Linthicum, "3 multicloud architecture patterns cloud pros should understand," InfoWorld, July 7, 2020.
52. Ibid.
53. Alfred Spector, Peter Norvig, and Slav Petrov, "Google's hybrid approach to research," Google, accessed October 13, 2020.
54. Rohit Kataria and Doug Dannemiller, "Will artificial intelligence transform investment research?," QuickLook Blog, Deloitte, November 15, 2018; Benzinga, "Financial advisors: Looking at active investing in a new way," Yahoo Finance, June 26, 2020.
55. Deloitte, "Alternative data investing," accessed October 13, 2020; Lorie Konish, "Morgan Stanley launches new advisory technology platform," CNBC, November 20, 2018.

Acknowledgments

The authors would like to thank **Neil Lesser, Bill Fera, Juergen Klenk, Aditya Kudumala, Lisa Noon, Rajeev Vasudeva, Vivien Bonazzi, Brett Davis, Bard Woltman, Kim Leggette, Christopher Larson** for sharing their expertise, as well as **Bryan Funkhouser, Sonal Shah, Wendy Gerhardt, Brenna Sniderman, Purnima Roy, Siddharth Mehrotra, Pankaj Sehgal, and Kavita Saini** for their time and contributions to this piece.

About the authors

Todd Konersmann | tkonersmann@deloitte.com

Todd Konersmann is a principal in Deloitte Consulting LLP's Life Sciences practice and is the national leader for the Life Sciences Information Technology practice. With more than 20 years of experience, he has led large global technology and business transformation programs for some of our largest and most notable clients. He has a passion for collaborating with clients to understand where and how to start adopting new technologies that help result in real value and improve the lives of patients worldwide.

Nicholas Merizzi | nmerizzi@deloitte.com

Nicholas Merizzi is a principal in the Deloitte Consulting LLP's Cloud Strategy offering and works with global organizations to help them achieve their cloud strategies at enterprise scale. He is skilled at helping clients to map a path for transformation, modernize complex distributed systems, and explore emerging technologies that enable business strategies. Merizzi brings more than 15 years of experience in technology across the financial services industry to his position.

Sudi Bhattacharya | sudibhattacharya@deloitte.com

Sudi Bhattacharya is a managing director with Deloitte Consulting LLP in Deloitte's Cloud Engineering practice. He leads big data and AI-/ML- driven business process transformation projects in public cloud environment for Fortune 500 businesses in finance, retail, CPG, and foodservice.

Diana Kearns-Manolatos | dkearnsmanolatos@deloitte.com

Diana Kearns-Manolatos is a senior manager in the Deloitte Center for Integrated Research where she analyzes market shifts and emerging trends across industries. Her research focuses on cloud and the future of workforce. Additionally, Manolatos draws on almost 15 years of award-winning marketing communications expertise to align insights with business strategy. She speaks on technology and women in leadership, and holds a bachelor's and master's degree from Fordham University.

Jay Parekh | japarekh@deloitte.com

Jay Parekh is a senior analyst with the Deloitte Center for Integrated Research. He has over five years of experience in research focused on emerging technologies and digital innovations related to augmented and virtual reality, Industry 4.0, the Internet of Things, cloud computing, and other advanced technologies. His primary focus is on applying quantitative and qualitative research techniques to enable data-driven insights.

Contact us

Our insights can help you take advantage of change. If you're looking for fresh ideas to address your challenges, we should talk.

Practice leadership

Todd Konersmann

Principal and US Life Sciences Information Technology leader | Deloitte Consulting LLP
+1 214 840 1993 | tkonersmann@deloitte.com

Todd Konersmann is a national leader for Life Sciences Information Technology practice for Deloitte Consulting LLP and is responsible for helping clients adopt new technologies and leading large global technology and business transformation programs.

Nicholas Merizzi

Principal | Cloud Strategy | Deloitte Consulting LLP
+ 617 610 6328 | nmerizzi@deloitte.com

Nicholas Merizzi is a principal in the cloud strategy offering within Deloitte Consulting LLP, and is responsible for helping clients achieve their cloud strategies at enterprise scale and explore emerging technologies that enable business strategies.

Sudi Bhattacharya

Managing director | Deloitte Consulting LLP
+1 214 840 7000 | sudibhattacharya@deloitte.com

Sudi Bhattacharya is a managing director with Deloitte Consulting LLP in Deloitte's Cloud Engineering practice. He is responsible for leading big data and AI/ML-driven business process transformation projects in public cloud environment for clients in finance, retail, CPG, and food services industries.

The Deloitte Center for Integrated Research

Diana M. Kearns-Manolatos

Senior manager, subject matter specialist | Deloitte Services LP
+1 212 436 3301 | dkearnsmanolatos@deloitte.com

Diana M. Kearns-Manolatos is a senior manager with Deloitte Services LP's Center for Integrated Research, where she focuses on cloud eminence and leads the annual Deloitte *MIT Sloan Management Review* Future of Workforce study.

About the Deloitte Center for Integrated Research

Deloitte's Center for Integrated Research focuses on developing fresh perspectives on critical business issues that cut across industries and functions, from the rapid change of emerging technologies to the consistent factor of human behavior. We look at transformative topics in new ways, delivering new thinking in a variety of formats, such as research articles, short videos, in-person workshops, and online courses.

Connect

To learn more about the vision of the Center for Integrated Research, its solutions, thought leadership, and events, please visit www.deloitte.com/us/cir.

Deloitte Cloud Consulting Services

Cloud is more than a place, a journey, or a technology. It's an opportunity to reimagine everything. It is the power to transform. It is a catalyst for continuous reinvention—and the pathway to help organizations confidently discover their possible and make it actual. Cloud is your pathway to possible. To learn more, visit Deloitte.com.

Deloitte.

Insights

Sign up for Deloitte Insights updates at www.deloitte.com/insights.



Follow @DeloitteInsight

Deloitte Insights contributors

Editorial: Kavita Saini, Aparna Prusty, Sayanika Bordoloi, and Nairita Gangopadhyay

Creative: Tushar Barman and Molly Woodworth

Promotion: Alexandra Kawecki

Cover artwork: Neil Webb

About Deloitte Insights

Deloitte Insights publishes original articles, reports and periodicals that provide insights for businesses, the public sector and NGOs. Our goal is to draw upon research and experience from throughout our professional services organization, and that of coauthors in academia and business, to advance the conversation on a broad spectrum of topics of interest to executives and government leaders.

Deloitte Insights is an imprint of Deloitte Development LLC.

About this publication

This publication contains general information only, and none of Deloitte Touche Tohmatsu Limited, its member firms, or its and their affiliates are, by means of this publication, rendering accounting, business, financial, investment, legal, tax, or other professional advice or services. This publication is not a substitute for such professional advice or services, nor should it be used as a basis for any decision or action that may affect your finances or your business. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser.

None of Deloitte Touche Tohmatsu Limited, its member firms, or its and their respective affiliates shall be responsible for any loss whatsoever sustained by any person who relies on this publication.

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the "Deloitte" name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.